Navigation Links
US Oncology Launches New Services Division: Innovent Oncology
Date:9/2/2008

tion of the Patient Support Services program.

"We've worked with oncologists and payers nationwide to develop this program," says Dr. Marcus Neubauer, Chairman of US Oncology's Level I Pathways committee and medical oncologist with Kansas City Cancer Centers. "The physicians affiliated with US Oncology developed evidence-based treatment pathways several years ago to reduce the high variability of drug utilization during treatment, but this program goes well beyond drug utilization in its quest for improved quality and reduced costs."

Innovent Oncology services were developed and have been in practical, community-based application for more than three years within the US Oncology network of member practices. While developed in the community setting, where more than 80 percent of the cancer care is delivered, this integrated approach to care is also applicable and easily implemented in hospital and academic settings.

"The strength of this program is the complete integration of payer and provider effort right in the physician's office," according to Kathy Lokay, Senior Vice President of Integrated Clinical Services for US Oncology. "Everyone wants clinically effective, cost-efficient care but, without true integration, there's either a duplication of effort or a communications gap that results in inefficiencies and a less than optimal patient experience."

About US Oncology

US Oncology, headquartered in Houston, works closely with physicians, manufacturers and payers to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology's expertise in supporting every aspect of the cancer care delivery system-from drug development to treatment and outcomes measurement-enables the company to help increase the effic
'/>"/>

SOURCE US Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
4. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
5. US Oncology to Report 2007 Third Quarter Earnings Results
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
8. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
9. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
10. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
11. National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National Greening Your School Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...J., Dec. 2 Cantel Medica... to discuss the Company,s results for its first qu...t 11:00 AM ET. Participating in the call will be ...esident; Craig A. Sheldon, Senior Vice President a...orporation. Minntech is a Cantel subsidiary. The f...
(Date:12/2/2008)... Ingenious Med (IM) welcomes new CE...der in inpatient practice,management solutions, w...are,software, revenue management, medical servic... nine-year CEO, Dr. Steven Liu, is confident Willi...opment in all sectors, as he steps into,the role....
(Date:12/2/2008)...moms who took it in first 3 months more likely to ...2 (HealthDay News) -- Infants whose mothers take f... an increased risk for respiratory illness, accord...ed to reduce the risk of birth defects, and many c... The researchers examined data on more than 32,000...
(Date:12/2/2008)... researchers at The University of Nottingham has i...cancer. , The research, published in the journal..., USA and funded by a 72,000 grant from the Britis...essor gene, LIMD1, is responsible for protecting t...y for possible new treatments and early screening ...
Breaking Medicine News(10 mins):Health News:Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008 2Health News:Ingenious Med Hires New CEO to Maintain and Further Expand Company Development 2Health News:Folate in Early Pregnancy May Boost Wheezing in Baby 2Health News:Gene which protects against lung cancer identified 2
...of developing pancreatic cancer increases by 90% w... // Pancreatic cancer risk was 70% higher in peopl...times a day when compared with those who added no ...r intake been already considered as a risk factor,...
...p of hospital services in east Lancashire by a cou...ers. // East Lancashire Hospitals NHS Trust has ... of Burnley's A&E department that will now not be ...the overview and scrutiny by the council’s committ...
...nother anti-polio drive Sunday even as new polio c... detected. During the drive, pulse polio drops wo...of up to five years of age, according to health of...case of polio was confirmed by the National Polio ...
...al Of American Medical Association announced that ... might not be completely bad. In fact a theory by ...as brought the association of heart attach and hig...r. Gheorghiade through his research found that dur...
Other Medicine News:Health News:Fury over Backing of Health Shake-up 2
(Date:11/25/2008)...nst expanding statin use broadly in wake of AHA-pr...25 JUPITER, a clinical trial sugge...sk of healthy patients with elevated CRP, should n...cording to a national poll directed at health prof...e online poll conducted by medical news site MedPa...
(Date:11/25/2008)... Poniard,Pharmaceutical...pany focused on,innovative oncology therapies, an... alternatives for its preclinical research program...urces on the clinical development of picoplatin,...tial commercialization of,picoplatin in the treat...
(Date:11/25/2008)...ial to Assess Survival of Patients Receiving Litx ... Hepatocellular Carcinoma , , BELLEVUE, Was...y, Inc. (LSO) today announced the completion of en...ht Infusion Therapy(TM) (Litx(TM)) as a treatment ...lso known as hepatoma or primary liver cancer. , ...
(Date:11/24/2008)...ov. 24 Takeda Pharmaceutical Compa... Global Research & Development Center, Inc., U...ommittee of the U.S. Food and Drug Administration ... for the treatment of hyperuricemia in patients wi...val, with one panel member abstaining. The vote fo...
Breaking Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Biophysical Society names 2009 award recipients 4751 1Biophysical Society names 2009 award recipients 4751 2Leaders in Pathology Meet in San Diego 3A Sept 25 28 2008 26107 1Leaders in Pathology Meet in San Diego 3A Sept 25 28 2008 26107 2HRSA Announces 2439 Million in Grants to Expand Improve Health Center Services 26105 1HRSA Announces 2439 Million in Grants to Expand Improve Health Center Services 26105 2Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year 7513 1Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year 7513 2
...pr 10, 2007 - Valeant,Pharmaceuticals Internationa...ase 2 data for retigabine, a first-in-class,neuron...ng,independent, scientific journal. The authors co...onstrated reduction in monthly,seizure rates in th... RESTORE2) are currently underway to further inves...
...es Insulin-Free, WASHINGTON, April 10, 2007 /PRNew...lt stem cell therapy, the Journal of the,American ...in which,14 of 15 Juvenile Diabetes patients demon...adult stem cell treatment. According,to U.S. Rep. ... in,that it,s the first attempt at using stem cell...
Other Medicine Technology:Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3Newest Adult Stem Therapy Treats Diabetes 2
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump.
...ARE TVT is a minimally invasive, highly effective ...rinary incontinence. GYNECARE TVT is positioned cl...when needed, TVT provides tension-free support of ... takes approximately 20 to 30 minutes, with minima...
SUR-FIT® AutoLock® Urostomy Pouch with Accuseal® Tap
New Image Urostomy Pouch, Ultra-Clear
Medicine Products: